Drela Katarzyna, Siedlecka Patrycja, Sarnowska Anna, Domanska-Janik Krystyna
NeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Acta Neurobiol Exp (Wars). 2013;73(1):38-56. doi: 10.55782/ane-2013-1920.
Here we provide a comprehensive data on the unique features of mesenchymal stem cells (MSCs) which makes them feasible and preferred candidate for cell-based therapy in neurological clinic. From this point of view the most important features of these cells are: (1) availability from autologous sources independently from age of patient; (2) extensive expansion in vitro; (3) immunomodulatory "bystander" function after transplantation in vivo; (4) potentiality to protect, repair or eventually replace impaired or dysfunctional host cells. For complete this last task of functional regeneration of central nervous system, we have to take advantages of MSCs capability for transient, time-locked proliferation, migration to site of injury and their commitment to neuronal differentiation. However, if we are to make progress in the use of MSCs for therapy in the clinic it will be necessary to establish more unified, advanced standards for cells processing in vitro as well as safer and improved procedures for their delivery in vivo.
在此，我们提供了关于间充质干细胞（MSCs）独特特征的全面数据，这些特征使其成为神经科临床基于细胞治疗的可行且首选候选者。从这一角度来看，这些细胞最重要的特征包括：（1）可从自体来源获取，与患者年龄无关；（2）在体外可大量扩增；（3）体内移植后具有免疫调节“旁观者”功能；（4）具有保护、修复或最终替代受损或功能失调宿主细胞的潜力。为了完成中枢神经系统功能再生的这一最终任务，我们必须利用间充质干细胞短暂、定时增殖、迁移至损伤部位以及向神经元分化的能力。然而，如果我们要在临床使用间充质干细胞进行治疗方面取得进展，就有必要建立更统一、先进的体外细胞处理标准以及更安全、改进的体内细胞递送程序。
